{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:21:15Z","timestamp":1783405275379,"version":"3.54.6"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    This study aimed to evaluate the safety and immunogenicity of a novel diphtheria, tetanus, and pertussis (acellular, three components) combined vaccine, adsorbed (DTcP) vaccine compared to the existing co-purified DTaP vaccine in China. In this partially randomized, blinded, controlled Phase III trial, we assessed a DTcP vaccine against two controls: a licensed co-purified DTaP and a DTaP-IPV-Hib vaccine. A total of 1,140 infants (3 months old) received a 3-dose primary series at 3, 4, and 5 months. Both of DTcP and co-purified DTaP had lower incidences of overall adverse reactions than the DTaP-IPV-Hib vaccine (17.99%\/18.08% vs. 21.96%). The DTcP vaccine demonstrated non-inferiority and superiority over the co-purified DTaP for anti-PT and anti-FHA immunogenicity. In addition, the DTcP achieved a 98.16% seroconversion rate for anti-FHA, versus only 14.29% for the co-purified DTaP. Besides, DTcP vaccine also induced high antibody level in GMC results. Specifically, the anti-PT GMC was 85.10 in the DTcP group versus 49.86 in the DTaP group (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&amp;lt;\u00a00.001) and 74.25 in the DTaP-IPV-Hib (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.001). For anti-FHA, the GMC was 108.28 in the DTcP group compared to only 10.69 in the DTaP group. In conclusion, DTcP vaccine induces a significantly more robust immune response to key pertussis antigens --compared to the co-purified DTaP, with a comparable safety profile. These data support the potential optimization of China\u2019s immunization strategy by transitioning from co-purified to component-based acellular pertussis vaccines to address waning immunity and the ongoing pertussis resurgence.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:related-object>\n                      <jats:ext-link>ClinicalTrial.gov<\/jats:ext-link>\n                      , identifier NCT05951725.\n                    <\/jats:related-object>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1874647","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:47:53Z","timestamp":1783403273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Henan Provincial Center for Disease Control and Prevention, Henan Key Laboratory of Infectious Pathogenic Microbiology","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wei","sequence":"additional","affiliation":[{"name":"National Institutes of Food and Drug Control","place":["Beijing, China"]},{"name":"State Key Laboratory of Drug Regulatory Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc.","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc.","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Xie","sequence":"additional","affiliation":[{"name":"Henan Provincial Center for Disease Control and Prevention, Henan Key Laboratory of Infectious Pathogenic Microbiology","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"National Institutes of Food and Drug Control","place":["Beijing, China"]},{"name":"State Key Laboratory of Drug Regulatory Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc.","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[{"name":"Henan Provincial Center for Disease Control and Prevention, Henan Key Laboratory of Infectious Pathogenic Microbiology","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Imstat Medical Technology CO., LTD","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Sui","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc.","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wan","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc.","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chao","sequence":"additional","affiliation":[{"name":"National Institutes of Food and Drug Control","place":["Beijing, China"]},{"name":"State Key Laboratory of Drug Regulatory Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Gou","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc.","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozhi","family":"Shi","sequence":"additional","affiliation":[{"name":"National Institutes of Food and Drug Control","place":["Beijing, China"]},{"name":"State Key Laboratory of Drug Regulatory Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"Henan Provincial Center for Disease Control and Prevention, Henan Key Laboratory of Infectious Pathogenic Microbiology","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc.","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyong","family":"Yuan","sequence":"additional","affiliation":[{"name":"National Institutes of Food and Drug Control","place":["Beijing, China"]},{"name":"State Key Laboratory of Drug Regulatory Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Henan Provincial Center for Disease Control and Prevention, Henan Key Laboratory of Infectious Pathogenic Microbiology","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","article-title":"Pertussis vaccines: WHO position paper - September 2015","volume":"90","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106289","article-title":"Global resurgence of pertussis: A perspective from China","volume":"89","author":"Liu","year":"2024","journal-title":"J Infect"},{"key":"B3","unstructured":"Pertussis\n          \n          2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00752-0","article-title":"Pertussis vaccination in Chinese children with increasing reported pertussis cases","volume":"22","author":"Zhang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2514943","article-title":"Clinical characteristics of pertussis in infants and risk factors for respiratory support","volume":"57","author":"Liru","year":"2025","journal-title":"Ann Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2392334","article-title":"Global tendency and frontiers of research on pertussis from 2000 to 2023: A bibliometric and visual analysis","volume":"20","author":"Wang","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.988549","article-title":"Characterization of co-purified acellular pertussis vaccines","volume":"11","author":"Xu","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055677","article-title":"Comparing the pertussis antibody levels of healthy children immunized with four doses of DTap-IPV\/Hib (Pentaxim) combination vaccine and DTaP vaccine in Quzhou, China","volume":"13","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2625556","DOI":"10.1080\/22221751.2026.2625556","article-title":"Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China","volume":"15","author":"Zhang","year":"2026","journal-title":"Emerg Microbes Infect"},{"key":"B10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpeds.2007.02.013","article-title":"Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a haemophilus influenzae type b conjugate vaccine","volume":"151","author":"Pichichero","year":"2007","journal-title":"J. Pediatrics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftv079","article-title":"Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential","volume":"73","author":"Scheller","year":"2015","journal-title":"Pathog Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.024","article-title":"Diphtheria vaccine: WHO position paper, August 2017","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit560","article-title":"Immune responses to pertussis vaccines and disease","volume":"209","author":"Edwards","year":"2014","journal-title":"J Infect Dis"},{"key":"B15","volume-title":"Pentaxim (Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, Haemophilus influenzae type b Conjugate Vaccine) Summary of Product Characteristics","year":""},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127279","article-title":"Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland","volume":"58","author":"Niinikoski","year":"2025","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1874647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:01Z","timestamp":1783403281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1874647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2026.1874647"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1874647","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1874647"}}